Health NCP Net 2.0 aims at improving and professionalizing the NCP service, thus achieving a more consistent level of NCP support services across Europe with the final goal to better support applicants and raise the average quality of proposals submitted. HNN 2.0 builds upon the experience and results of the previous Health NCP Net project with the objective of responding to the new challenges that the “Health, Demographic Change and Wellbeing” NCPs face in the new programme Horizon 2020, such as the broadened thematic scope of the Societal Challenge 1, and the enlarged mandate of the “Health” NCPs. An objective of the HNN 2.0 project is to satisfy the needs and priorities of all different types of NCPs, notably newcomers, NCPs with fewer resources, NCPs from EU-13 and NCPs in Third Countries so as to face the challenge of the current heterogeneity of the network The enlarged mandate of “Health” NCPs and the holistic focus of H2020 imply that NCPs need to create expert knowledge and look for it outside the SC1 Network by having a holistic approach and liaising and collaborating with other support structures, projects and programmes. HNN 2.0 will therefore have a real structured coordination with the other NCP and support networks such as Ideal-IST, EEN and Fit for Health 2.0, where collaboration for joint activities like training courses, meet and exchange workshops and brokerage events is established. Main tools towards the objectives: - support and information materials - comprehensive training programme - mentoring programme (staff exchanges, mentoring programme for EU-13, twinning with the European Commission) - Meet and Exchange workshops with NCPs from other disciplines - system of email alert for NCPs about research funding and related policies - information and communication hub for SC1-NCPs (easy access to information and services , exchange of information and opinions between SC1-NCPs) - International brokerage events

Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.

The detection of infectious disease emergence relies on reporting cases, i.e. indicator-based surveillance (IBS). This method lacks sensitivity, due to non or delayed reporting of cases. In a changing environment due to climate change, animal and human mobility, population growth and urbanization, there is an increased risk of emergence of new and exotic pathogens, which may pass undetected with IBS. Hence, the need to detect signals of disease emergence using informal, multiple sources, i.e. event-based surveillance (EBS). The MOOD project aims at harness the data mining and analytical techniques to the big data originating from multiple sources to improve detection, monitoring, and assessment of emerging diseases in Europe. To this end, MOOD will establish a framework and visualisation platform allowing real-time analysis and interpretation of epidemiological and genetic data in combination with environmental and socio-economic covariates in an integrated inter-sectorial, interdisciplinary, One health approach: 1)Data mining methods for collecting and combining heterogeneous Big data, 2)A network of disease experts to define drivers of disease emergence, 3)Data analysis methods applied to the Big data to model disease emergence and spread, 4)Ready-to-use online platform destined to end users, i.e. national and international human and veterinary public health organizations, tailored to their needs, complimented with capacity building and network of disease experts to facilitate risk assessment of detected signals. MOOD output will be designed and developed with end users to assure their routine use during and beyond MOOD. They will be tested and fine-tuned on air-borne, vector-borne, water-borne model diseases, including anti-microbial resistance. Extensive consultations with end users, studies into the barriers to data sharing, dissemination and training activities and studies on the cost-effectiveness of MOOD output will support future sustainable user uptake

PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies with new data, knowledge, methods, networks and skills to address current, emerging and novel chemical safety challenges. PARC will facilitate the transition to next generation risk assessment to better protect human health and the environment, in line with the Green Deal?s zero-pollution ambition for a toxic free environment and will be an enabler for the future EU ?Chemicals Strategy for Sustainability?. It builds in part on the work undertaken and experience acquired in past and on-going research and innovation actions, but goes beyond by its vocation to establish an EU-wide risk assessment hub of excellence. To contribute to several expected impacts of destination 2 ?Living and working in a health-promoting environment?, PARC will organise the activities to reach three specific objectives: - An EU-wide sustainable cross-disciplinary network to identify and agree on research and innovation needs and to support research uptake into regulatory chemical risk assessment. - Joint EU research and innovation activities responding to identified priorities in support of current regulatory risk assessment processes for chemical substances and to emerging challenges. - Strengthening existing capacities and building new transdisciplinary platforms to support chemical risk assessment. The Partnership brings together Ministries and national public health and risk assessment agencies, as well as research organisations and academia from almost all of EU Member States. Representatives of Directorates-General of the EC and EU agencies involved in the monitoring of chemicals and the assessment of risks are also participating. PARC will meet the needs of risk assessment agencies to better anticipate emerging risks and respond to the challenges and priorities of the new European policies.